Trial Profile
A Phase II Study of Alemtuzumab and Pentostatin In T-Cell Neoplasms.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Pentostatin (Primary)
- Indications Peripheral T-cell lymphoma; T-cell lymphoma; T-cell prolymphocytic leukaemia
- Focus Therapeutic Use
- 16 Mar 2010 Actual patient number (26) added as reported by ClinicalTrials.gov.
- 16 Mar 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Mar 2010 Planned end date changed from 1 Feb 2011 to 1 Mar 2010 as reported by ClinicalTrials.gov.